Aoxiang Pharmaceutical announced on November 2. Recently, SpiRig HealthCare AG, a subsidiary of the company's partner StadaArzneimittel AG, received a marketing license for rucotinib tablets approved and issued by the Swiss Medicines Administration. This formulation product is one of the products jointly developed and commercialized by the company and STADA. The company undertakes the production task of this formulation product, while the sales work is carried out separately by both parties in their respective responsible market regions.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.